Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line

A. B H Bakker, M. W J Schreurs, G. Tafazzul, A. J. De Boer, Yutaka Kawakami, G. J. Adema, C. G. Figdor

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

Cytotoxic T lymphocytes (CTL) reactive with human melanoma tumor cells occasionally display cross-reactivity with normal melanocytes. Previously, we identified the melanocyte lineage-specific antigen gp100 that is expressed by both melanoma cells and normal melanocytes, as a target antigen for tumor-infiltrating lymphocytes derived from a melanoma patient (TIL 1200). Here, we demonstrate that the oligoclonal HLA-A2.1-restricted TIL 1200 line is reactive with 2 distinct peptides derived from the gp100 protein. Apart from the peptide corresponding to gp100 amino acids 457-466, we identified the gp100 peptide 154-162 as a second epitope recognized by TIL 1200. A 100-fold lower concentration of this novel gp100 peptide was required for target-cell sensitization compared to peptide 457-466, indicating that the 154-162 peptide is the dominant gp100 epitope for TIL 1200. Together with the recently described gp100 280-288 epitope, 3 distinct CTL epitopes have now been identified in gp100, all presented in the context of HLA-A2.1. Therefore, gp100 is an attractive target antigen in the development of immune-therapeutic protocols against melanoma.

Original languageEnglish
Pages (from-to)97-102
Number of pages6
JournalInternational Journal of Cancer
Volume62
Issue number1
DOIs
Publication statusPublished - 1995
Externally publishedYes

Fingerprint

Melanocytes
Cytotoxic T-Lymphocytes
Epitopes
Melanoma
Antigens
Peptides
gp100 Melanoma Antigen
Tumor-Infiltrating Lymphocytes
T-Lymphocyte Epitopes
Amino Acids
Neoplasms
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line. / Bakker, A. B H; Schreurs, M. W J; Tafazzul, G.; De Boer, A. J.; Kawakami, Yutaka; Adema, G. J.; Figdor, C. G.

In: International Journal of Cancer, Vol. 62, No. 1, 1995, p. 97-102.

Research output: Contribution to journalArticle

Bakker, A. B H ; Schreurs, M. W J ; Tafazzul, G. ; De Boer, A. J. ; Kawakami, Yutaka ; Adema, G. J. ; Figdor, C. G. / Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line. In: International Journal of Cancer. 1995 ; Vol. 62, No. 1. pp. 97-102.
@article{d5193b5952394efd8cfb96f4f78fbdb8,
title = "Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line",
abstract = "Cytotoxic T lymphocytes (CTL) reactive with human melanoma tumor cells occasionally display cross-reactivity with normal melanocytes. Previously, we identified the melanocyte lineage-specific antigen gp100 that is expressed by both melanoma cells and normal melanocytes, as a target antigen for tumor-infiltrating lymphocytes derived from a melanoma patient (TIL 1200). Here, we demonstrate that the oligoclonal HLA-A2.1-restricted TIL 1200 line is reactive with 2 distinct peptides derived from the gp100 protein. Apart from the peptide corresponding to gp100 amino acids 457-466, we identified the gp100 peptide 154-162 as a second epitope recognized by TIL 1200. A 100-fold lower concentration of this novel gp100 peptide was required for target-cell sensitization compared to peptide 457-466, indicating that the 154-162 peptide is the dominant gp100 epitope for TIL 1200. Together with the recently described gp100 280-288 epitope, 3 distinct CTL epitopes have now been identified in gp100, all presented in the context of HLA-A2.1. Therefore, gp100 is an attractive target antigen in the development of immune-therapeutic protocols against melanoma.",
author = "Bakker, {A. B H} and Schreurs, {M. W J} and G. Tafazzul and {De Boer}, {A. J.} and Yutaka Kawakami and Adema, {G. J.} and Figdor, {C. G.}",
year = "1995",
doi = "10.1002/ijc.2910620118",
language = "English",
volume = "62",
pages = "97--102",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line

AU - Bakker, A. B H

AU - Schreurs, M. W J

AU - Tafazzul, G.

AU - De Boer, A. J.

AU - Kawakami, Yutaka

AU - Adema, G. J.

AU - Figdor, C. G.

PY - 1995

Y1 - 1995

N2 - Cytotoxic T lymphocytes (CTL) reactive with human melanoma tumor cells occasionally display cross-reactivity with normal melanocytes. Previously, we identified the melanocyte lineage-specific antigen gp100 that is expressed by both melanoma cells and normal melanocytes, as a target antigen for tumor-infiltrating lymphocytes derived from a melanoma patient (TIL 1200). Here, we demonstrate that the oligoclonal HLA-A2.1-restricted TIL 1200 line is reactive with 2 distinct peptides derived from the gp100 protein. Apart from the peptide corresponding to gp100 amino acids 457-466, we identified the gp100 peptide 154-162 as a second epitope recognized by TIL 1200. A 100-fold lower concentration of this novel gp100 peptide was required for target-cell sensitization compared to peptide 457-466, indicating that the 154-162 peptide is the dominant gp100 epitope for TIL 1200. Together with the recently described gp100 280-288 epitope, 3 distinct CTL epitopes have now been identified in gp100, all presented in the context of HLA-A2.1. Therefore, gp100 is an attractive target antigen in the development of immune-therapeutic protocols against melanoma.

AB - Cytotoxic T lymphocytes (CTL) reactive with human melanoma tumor cells occasionally display cross-reactivity with normal melanocytes. Previously, we identified the melanocyte lineage-specific antigen gp100 that is expressed by both melanoma cells and normal melanocytes, as a target antigen for tumor-infiltrating lymphocytes derived from a melanoma patient (TIL 1200). Here, we demonstrate that the oligoclonal HLA-A2.1-restricted TIL 1200 line is reactive with 2 distinct peptides derived from the gp100 protein. Apart from the peptide corresponding to gp100 amino acids 457-466, we identified the gp100 peptide 154-162 as a second epitope recognized by TIL 1200. A 100-fold lower concentration of this novel gp100 peptide was required for target-cell sensitization compared to peptide 457-466, indicating that the 154-162 peptide is the dominant gp100 epitope for TIL 1200. Together with the recently described gp100 280-288 epitope, 3 distinct CTL epitopes have now been identified in gp100, all presented in the context of HLA-A2.1. Therefore, gp100 is an attractive target antigen in the development of immune-therapeutic protocols against melanoma.

UR - http://www.scopus.com/inward/record.url?scp=0029028642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029028642&partnerID=8YFLogxK

U2 - 10.1002/ijc.2910620118

DO - 10.1002/ijc.2910620118

M3 - Article

VL - 62

SP - 97

EP - 102

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1

ER -